Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIPAS
2024-515363-63-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 20 and PCV21 in asplenia and Susceptibility to Streptococcus pneumoniae infection (3 arms), sponsored by Leiden University Medical Center. Planned start Aug 2025; status: authorised.
02
Drugs
Prevnar 20PCV21
03
Conditions
aspleniaSusceptibility to Streptococcus pneumoniae infection
Beyond the preview
Go deeper on 2024-515363-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515363-63-00.